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Abbreviations 
AE Adverse event 
BPO Benign Prostatic Obstruction  
BRTC Bristol Randomised Trials Collaboration 
CACE Complier Average Causal Effect 
DRE Digital Rectal Examination 
GA General Anaesthetic  
ICIQ-MLUTS International Consultation of Incontinence Questionnaires on Male LUTS 
ICIQ-MLUTS-sex International Consultation of Incontinence Questionnaires on Male LUTS 
sexual function 
IIEF International Index of Erectile Function Questionnaire 
IPSS International Prostate Symptom Score 
ITT Intention To Treat 
LUTS Lower Urinary Tract Symptoms 
MAR Missing At Random 
NHS National Health Service 
PI Principal Investigator 
PIS Patient Information Sheet 
Qmax Maximum urinary flow rate 
QoL Quality of Life 
ThuVARP Thulium laser transurethral vaporesection of the prostate 
TURP Transurethral Resection of the Prostate 
UK United Kingdom 
UTI Urinary Tract Infection 
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1. Introduction & Purpose 
This document details the proposed rules and presentation to be followed, as closely as possible, 
when analysing and reporting the main results from the UNBLOCS trial: Urinary obstruction relieved 
by laser or conventional transurethral surgery 
The purpose of the plan is to:  
 Pre-specify the analysis prior to examining the outcome data 
 Ensure that the analysis is appropriate for the aims of the trial, reflects good statistical 
practice, and that interpretation of a priori and post hoc analyses respectively is appropriate. 
 Explain in detail how the data will be handled and analysed to enable others to perform the 
analysis in the event of sickness or other absence. 
Additional exploratory or auxiliary analyses of data not specified in the protocol are permitted but 
fall outside the scope of this analysis plan (although such analyses would be expected to follow Good 
Statistical Practice). 
The analysis strategy will be made available, if required, to journal editors or referees when the main 
papers are submitted for publication.  Additional analyses suggested by reviewers or editors will, if 
considered appropriate, be performed in accordance with the analysis plan, but, if reported, the 
source of such a post-hoc analysis will be declared. 
Amendments to the statistical analysis plan will be described and justified in the final report of the 
trial. 
2. Trial Synopsis  
This is a summary of the study design as described in the study Protocol (version 10, 4th May 2017) 
with the single purpose of ensuring an informed statistical analysis. For all other purposes reference 
MUST be made to the current version of the protocol (if different from version noted above). 
 
2.1 Rationale  
As men get older their prostates get bigger. This commonly results either in urinary retention, when 
the man cannot pass urine, or in bothersome lower urinary tract symptoms (LUTS) secondary to 
benign prostatic obstruction (BPO). If medical therapy fails to improve these symptoms, men often 
request surgery to reduce their LUTS, and relieve the obstruction, in order to allow them to void 
better, and prevent the complications associated with BPO. 
Around 25,000 prostate operations are performed annually in the UK for men with benign prostatic 
obstruction (BPO) to relieve obstruction, with transurethral resection of the prostate (TURP), the 
gold standard operation, accounting for around 80% of these operations. TURP has been used widely 
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for the last 40 years, and although it is generally a successful procedure, it is associated with small 
but significant risks for the patient.  
Currently available data suggests that thulium laser transurethral vaporesection of the prostate 
(ThuVARP) can potentially reduce blood loss, shorten hospital stay with an increased proportion 
conducted as day-cases, allow an earlier return to normal activities, shorten duration of 
catheterisation and reduce incidence of TUR syndrome. Thus the ThuVARP procedure has the 
potential to offer significant health and quality of life benefits to patients at reduced cost to the 
NHS. The key aim of this research is to determine whether ThuVARP is equivalent to TURP in men 
with lower urinary tract symptoms secondary to benign prostatic obstruction (BPO) treated within 
the NHS, judged on a patient reported symptom severity score (IPSS) and the maximum urine flow 
rate (Qmax); therefore two primary outcomes. 
 
2.2 Trial Design 
UNBLOCS is a two arm, multi-centre, pragmatic, parallel-group RCT randomising men with benign 
prostatic obstruction (BPO) to either ThuVARP or TURP. Randomisation will be at the patient level so 
men will be randomised to receive either ThuVARP or TURP. The study was designed as an 
equivalence trial with an equivalence margin of 2.5 on the IPSS scale and 4ml/s on the Qmax scale. 
With respect to the IPSS outcome, if the 95% confidence interval of the difference (ThuVARP-TURP) 
lies above 2.5 or below -2.5 then the two surgical procedures will be deemed non-equivalent. 
Therefore our null hypothesis is that a difference of at least 2.5 exists. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[Adapted from Piaggio G, Elbourne DR et al.i] 
In the scenarios illustrated above, scenarios B and E would result in the conclusion that the two 
procedures are equivalent. However, in scenarios A and D one may be considered superior to the 
other, given that testing first for equivalence before superiority does not require a statistical penalty 
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for multiple testing.ii The illustration is very similar for the Qmax outcome with the signs reversed (as 
higher values are positive outcomes) and an equivalence margin of 4 rather than 2.5.  
 
2.3 Trial Centres 
Men suitable for prostate surgery will be recruited and operated on at seven centres; four university 
teaching hospitals (Bristol, Aberdeen, Newcastle, Leeds) and three district general hospitals 
(Swindon, Cheltenham, Truro). As this is a pragmatic study, centres will continue to use their usual 
practices, e.g. monopolar or bipolar TURP.  
 
2.4 Study Population  
2.4.1 Target Population 
Men over the age of 18 who are suitable for prostate surgery. Men may request surgery to reduce 
their LUTS, relieve obstruction and prevent complications associated with BPO, e.g. UTI.  
2.4.2 Inclusion Criteria 
- As this is a pragmatic trial, it will include men (aged≥18) who are suitable for TURP referred to 
secondary care for assessment with a view to requiring benign prostatic obstruction (BPO) surgery 
for either bothersome lower urinary tract symptoms (LUTS), or urinary retention, secondary to BPO. 
2.4.3 Exclusion Criteria 
- Neurogenic LUTS (these patients do not usually require BPO surgery). 
- Prostate cancer. 
- Previous prostate (methodological) or urethral surgery (methodological). 
- Men with a PSA outside of the normal age-related range and who have not had prostate cancer 
excluded. 
- Men who are unable to give informed consent or complete trial documentation. This assessment 
will be made by a study doctor or research nurse who has appropriate training and responsibility for 
taking consent. 
 
2.5 Intervention 
ThuVARP uses laser technology to vaporise and resect the prostate while TURP uses electric current 
to resect the prostate. ThuVARP essentially uses the same surgical skill-set as for the TURP 
procedure which is part of core practice for all urologists, including our trial surgeons who will 
perform both procedures. Transurethral resection of the prostate (TURP) is the ‘gold standard’ 
operation to relieve obstruction in the UK and worldwide, and has been the most frequently 
performed procedure for 40 years. 
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2.6 Compliance 
As this is a pragmatic trial, surgical procedure and postoperative care will be according to local 
centre practice. Concomitant procedures will be recorded and reported.  
 
To promote fairness in the assessment of the outcomes of the operations, participants will not be 
informed of their study arm allocation, although their GP will be able to access this information, and 
participants will be made aware of this, and the reason behind it, before consent. After the 
participant has entered the study the clinician remains free to give alternative treatment to that 
specified in the protocol at any stage if he/she feels it is in the participant’s best interest, but the 
reasons for doing so should be recorded. In these cases the participants remain within the study for 
the purposes of follow-up and data analysis. All participants are free to withdraw at any time from 
the protocol treatment without giving reasons and without prejudicing further treatment. 
 
2.7 Research Objectives 
2.7.1 Primary 
(1) What is the relative clinical effectiveness of ThuVARP and TURP in improving patient 
reported lower urinary tract symptoms (LUTS) as measured by the International Prostate 
Symptoms Score (IPSS) patient reported questionnaire, and the objective measure of 
maximum urinary flow rate (Qmax), 12 months after surgery? Where a 2.5 point difference 
on the IPSS scale and 4ml/s difference on the Qmax is considered equivalent. 
2.7.2 Secondary 
(1) How do the two procedures compare in terms of peri-operative outcomes? 
- Clavien Dindo scoring of surgical complications 
- Length of hospital stay and transfusion rates 
(2) What is the cost-effectiveness of ThuVARP as compared to TURP in terms of the two primary 
outcomes and quality-adjusted-life-years (QALYs)?* 
(3) What is the comparative impact of each treatment on patient-reported LUTS, erectile 
function, quality of life and general health at 6 weeks after randomisation/surgery, 3 months 
and 12 months  
- ICIQ-MLUTS 
- ICIQ-MLUTSsex/IIEF-5 
- ICIQ-LUTSqol 
(4) What is the comparative satisfaction of men with each type of surgery? 
- ICIQ-satisfaction 
(5) What is the comparative effectiveness of these operations in men who present with LUTS as 
opposed to urinary retention?  
(6) What are men’s experiences of both procedures, including those presenting with LUTS or 
urinary retention?* 
 
*These objectives are not part of the statistical analysis 
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2.8 Recruitment 
The UNBLOCS trial began recruitment in June 2014, with the first participant enrolled on 23 July 
2014. Recruitment completed on 31st December 2016. 
 
2.9 Randomisation Procedures 
Randomisation will be at the patient level and will be stratified by centre and whether the patient 
was eligible due to bothersome LUTS or urinary retention. Randomisation will employ random sized 
blocking and will be carried out by the UKCRC accredited Bristol Randomised Trials Collaboration 
(BRTC). 
 
2.10 Sample Size Calculation 
2.10.1 Equivalence margin 
The sample size calculation is based on the consideration that men randomised to ThuVARP should 
have clinical outcomes which are equivalent to those who are randomised to TURP. For the primary 
outcomes, a difference in LUTS score of no more than 2.5 points (on IPSS scale) and of 4m/s for 
Qmax suggests equivalence. The team felt that these were appropriate for the following reasons: 
- The minimally clinically important difference (MCID) for the IPSS score is generally 
accepted to be a 3 point difference, however a previous trialiii of ThuVARP vs. TURP used 
an MCID of 2 points. This previous trial witnessed a very small difference of only 0.4 on 
the IPSS scale. The team felt that a level between these would be more suitable.  
- There is no minimally clinical important difference in flow rate that is accepted in the 
literature, however 2ml/s has been quoted previouslyiv.   
- Discussions between clinicians, both in the trial team and with other urologists, were 
used to reach an overall consensus that the maximum acceptable differences would be a 
flow rate of 4ml/s and 2.5 points or less on the IPSS. 
 
2.10.2 Sample size 
This study is powered to establish equivalence in clinical improvement. A Chinese trialiii observed 
differences of 0.4 ml/s (95% CI: -2.0 to 2.8) in Qmax and 0.4 units (-0.7 to 1.5) in IPSS between 
ThuVARP and TURP. Variability (standard deviation; SD) in data at 12 months was approximately 6.0 
ml/s (Qmax) and 3.0 units (IPSS), but previous trials of TURP report greater variability, around 9 ml/s 
(Qmax) and 5 units IPSSv,vi. We have specified differences of 4 ml/s in Qmax and 2.5 units in IPSS, as 
demonstrating equivalence. Equivalence studies often use an alternative hypothesis of a difference 
of zero between treatments. However, the Chinese trial observed differences of around 0.4 ml/s and 
0.4 units for Qmax and IPSS. Incorporating these as alternative hypotheses ensures adequate power 
to demonstrate equivalence if treatments are indeed similar but not identical. 
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Assuming SDs of 9 ml/s for Qmax and 5 units for IPSS, the target sample size for patients needed to 
complete the 12-month follow-up was 163 patients in each group. Using NQuery Advisor, this will 
provide 85% power to demonstrate equivalence for Qmax and just over 90% power for IPSS, at a 
two-sided alpha of 5%. Assuming 20% loss to follow-up following randomisation, it was necessary to 
recruit 410 men in total. This loss to follow-up is a conservative estimate from our experience of 
previous trials. However, we are aiming to reduce loss to follow-up through letter, text and 
telephone reminders to patients. 
 
2.11 Blinding 
To reduce bias in the assessment of outcomes, participants were not informed of their study arm 
allocation, although their general practitioner (GP) can access this information. Participants were 
informed that, although it would be preferred that they did not know which operation they have 
had; their GP will not be prevented from giving them this information if they request it. We 
anticipated that some men will ask for, or discover, their allocation at some point during the study 
and we will be asking them to reveal when and how they became aware of this in the 12-month 
follow-up questionnaire.  
All investigators remained blinded throughout recruitment and analysis of patients. The senior 
statistician, Chris Metcalfe had not seen any data when writing this SAP and will remain blinded 
throughout the analysis. The junior statistician, Grace Young, had access to a small subset of patients 
(20) while helping to write the analysis plan.   
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3. Statistical Analysis 
3.1 Software 
Stata 14.1 (or a later version) will be used for analysis of the UNBLOCS study.  
 
3.2 Data Collection 
Data will be collected at certain points for the various data collection forms. The IPSS score will have 
been collected at baseline, 6 weeks, 3 months and 12 months whereas the Qmax will be collected at 
baseline, 3 months and 12 months. The ICIQ urinary, sexual, QoL and satisfaction questions will also 
be asked at these time points; as will the EQ5D.   
 
3.3 Distributions 
Where the distribution of the outcomes is approximately normal, mean values with standard 
deviations will be presented. For baseline characteristics, where the distribution of the outcome is 
not approximately normal, suitable transformations or medians and interquartile ranges (IQR) will 
be presented. For binary/categorical variables, a number and percentage will be presented.  
For the continuously measured outcomes in the primary and secondary analyses, where outcomes 
are clearly non-normal, transforming to improve the normality of the residuals in the regression 
models will be explored. The choice of whether or not to transform variables, and if so which 
transformation to use, will be decided by considering:  
(1) The distribution of the variable 
 STUDY PERIOD 
 Enrolment Allocation Post-allocation 
Time point Baseline Day of surgery Post-operative 6 weeks 3 months 12 months 
Case report form       
ICIQ-Bladder diary       
Maximum urinary flow 
rate (Qmax) 
      
Post-void residual and 
Voided volume 
      
Full blood count       
Urea & Electrolytes       
IPSS       
ICIQ-MLUTS       
ICIQ-MLUTSsex/IIEF-5       
ICIQ-LUTSqol       
EQ-5D-5L       
ICIQ-satisfaction       
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(2) The distribution of residuals from regression models 
(3) The ease of interpreting results following any given transformation compared with no 
transformation 
(4) Whether main results/conclusions are influenced by the transformation or not.  
 
3.4 Withdrawal 
Participants will remain in the trial unless they choose to withdraw or if they are unable to continue 
for a clinical reason. If a participant withdraws consent, further participant questionnaires will not be 
collected. However permission will be sought for the research team to continue to collect outcome 
data from their health care records. Participants are informed in the PIS that they have the right to 
withdraw all personal data held by the study. Study specific procedures for a participant’s change of 
permissions, or withdrawal, are outlined in the relevant trial working guidelines that are provided to 
each site. This guidance includes mandatory reporting procedures by sites to the central office 
(BRTC). The withdrawals from both arms will be recorded and a chi squared test will be performed to 
compare the difference in the number of withdrawals between the arms. Men may also choose to 
change permissions, e.g. request no further clinical tests but continue completing questionnaires, 
these will be compared in the same way.  
 
3.5 Baseline Characteristics 
Baseline characteristics will be compared between the two arms by reporting relevant summary 
statistics in order to determine whether any potentially influential imbalance occurred, by chance, 
between the two arms. Characteristics will be reported as means (sd), medians (IQR) or number (%) 
depending on the nature of the data and its respective distribution as defined in section 3.3.3. If the 
baseline characteristics of the two groups differ by more than 10% or half a standard deviation then 
the effect of this variable on the outcome will be investigated in a sensitivity analysis.  
 
3.6 Analysis of Effectiveness 
3.6.1 Analysis Populations 
•ITT Analysis set: All randomised participants: analyses will be based on the intention-to-treat 
principle (ITT), analysing men in the groups to which they were randomised. 
•Per protocol analysis set: Only including those who complied with their allocated treatment and 
did not deviate from the protocol.  
 
3.6.2 Primary Analysis 
The primary comparative analyses will be conducted on an ‘as allocated’ basis and will employ 
multivariable linear regression to investigate equivalence in Qmax and IPSS between ThuVARP and 
TURP at 12 months. The null hypothesis is that the two surgical procedures differ by at least 2.5 and 
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4 in their IPSS and Qmax score respectively, while the alternative hypothesis is that the two 
procedures are equivalent. Analyses will adjust for stratification variables (centre and baseline 
LUTS/retention). Interpretation of results will focus on observed differences, and 95% confidence 
intervals for the between-group comparisons, to determine whether clinically important differences 
between ThuVARP and TURP are unlikely. The null hypothesis for the primary analysis is “difference 
in IPSS/Qmax between the groups”. 
𝑦𝑖 =  𝛽0 +  𝛽1𝑥1 + 𝛽2𝑥2 + 𝛽3𝑥3 +  𝑒𝑖 
Where 𝑦 is IPSS/Qmax, 𝛽1 is the parameter regression co-efficient for group and 𝑥1 is the variable 
group (1= ThuVARP, 0=TURP). Variables 𝑥2 and 𝑥3 are the potential confounding variables that are 
being adjusted for; centre and retention status. 𝑒𝑖 represents the error term for patient i. 
As stated in the protocol, the primary analysis will account for missing data. We will explore the 
implications of this by conducting a complete case analysis as a sensitivity analysis. Missing data for 
the primary outcome, assumed to be MAR (missing at random), will be imputed under conservative 
assumptions and the effect of missing data investigated. The handling of missing data will follow the 
principles specified in the EMA/CPMP/EWP/1776/99 Rev1 and any changes to the methods 
described here will be fully justified in the study report and publication. For the imputation model 
adopted, a pre-specified random seed of 525 has been chosen. The trial team anticipates that 
missing data will be MAR and therefore a multiple imputation approach is appropriate to evaluate 
the difference in treatments, at 12 months, while accounting for missing IPSS/Qmax levels. Data 
from the 6 week and 3 month time points will be used to inform the imputation process. The main 
primary analysis will not adjust for baseline IPSS/Qmax score as those with retention are unlikely to 
have relevant or appropriate scores. We will however factor baseline IPSS and baseline Qmax in 
subsequent sensitivity analyses.  
  
3.6.3 Secondary Analyses 
(1) Clavien-Dindo (scale 1-5) classification of surgical complications; the number of 
complications experienced per patient will be explored, along with the worst event per 
patient using ordinal logistic regression. If there are sufficient numbers then we will also 
explore the data at the event level, using descriptive data only. 
1. Deviation from normal postoperative course without the need for further 
interventions (pharmaceutical, surgical etc.) 
2. Requiring pharmacological treatment 
3. Requiring surgical intervention (a) not under GA or (b) under GA 
4. Life-threatening complication: (a) single or (b) multi organ failure 
5. Death of patient 
(2) Length of hospital stay will be analysed using linear regression while transfusion rates will 
be measured using logistic regression.  
(3) Comparative impact of each treatment on patient-reported LUTS, erectile function, quality 
of life and general health at 6 weeks after randomisation/surgery, 3 months and 12 months. 
Measured using the:  
- ICIQ Male LUTS (ICIQ-MLUTS) 
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- ICIQ sexual function in Male LUTS (ICIQ-MLUTS-sex) 
- IIEF-5 
- ICIQ quality of life (ICIQ-LUTSqol) 
- IPSS QoL 
These measures will be analysed using linear and logistic regression as appropriate. 
(4) Comparative satisfaction of men with each type of surgery, measured using the ICIQ-
satisfaction, analysed using logistic and ordinal logistic regression as appropriate. 
(5) Post-operative catheterisation time, a continuous variable, measured from the time of 
surgery to the time of TWOC. This will be measured using a time to event analysis technique 
such as a cox proportional hazards model. We will also report on whether the patient still 
has a catheter at 3 month and 12 months, analysed using logistic regression] 
(6) Haemoglobin – blood loss during surgery, analysed using linear regression. 
(7) Serum sodium – absorption of irrigation fluid, analysed using linear regression. 
(8) Post-void residual urine, analysed using linear regression. 
Should the assumptions of these analyses not be met, alternative transformations or non-parametric 
methods may be utilised.  
 
3.6.4 Subgroup analyses 
Formal tests of interaction between the dichotomised variables and treatment pathway will be 
carried out to test whether treatment effect differs between patients. These subgroup analyses will 
be applied to the two primary analyses (IPSS and Qmax score): 
- Baseline diagnosis of LUTS vs. urinary retention 
- Age (split by the median age) 
- Pre-operative prostate size measure by DRE (small <40g, medium 40-60g, large 60-80g 
and very large >80g) 
- Patients with or without co-morbidities at baseline (based on the Charlson Index) 
 
In the protocol we had specified that we would look at the length of stay of procedures (daycase or 
inpatients). However, it was later decided that this would be more suitable as an outcome only as 
the baseline intention would be unlikely to alter the treatment effect on IPSS scores/Qmax. 
 
3.6.5 Sensitivity Analysis 
Several sensitivity analyses will be conducted to test the robustness of the results from the statistical 
analyses, and in some cases, to increase understanding of the relationship between the dependent 
and independent variables:  
1. Complete case analysis 
The primary analysis will be repeated, without imputation for missing variables 
2. Per Protocol analysis 
The Per Protocol analysis allows assessment of treatment effect among those who received the 
treatment that they were assigned to. Both TURP and ThuVARP have an array of concomitant 
treatments; the appropriateness of which will be agreed in advance of analysis.  
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3. CACE analysis 
The Complier Average Causal Effect (CACE) analysis allows unbiased assessment of treatment effect 
which analyses patients according to the treatment they received and uses random allocation as an 
instrumental variables.  
4. Removal of patients 
Patients who have found out their allocation (not including those who guess correctly) prior to 
completing the 12 month questionnaire and follow up will be removed from the cohort in this 
sensitivity analysis. 
5. Adjustment for baseline 
The two primary outcomes (IPSS and Qmax) will be adjusted for their respective baseline measures. 
Clinically sensible values will be imputed for those with retention, such as the lowest score of those 
recorded. If this proves difficult, baseline measures may be graded by severity and those with 
catheters placed in the most severe category.  
6. Adjustment for imbalance at baseline 
As described in section 3.5, covariates that differ at baseline by more than half a standard deviation 
(or 10%) will be added to the model concurrently to investigate their effect on the difference 
observed between the two groups. 
7.  Type of TURP/surgery 
Although originally listed in the protocol as a sub group analysis we will analyse TURP separately 
alongside ThuVARP; therefore comparing 3 groups ThuVARP, monopolar TURP and bipolar TURP. 
8.  Surgeon effects 
A mixed-effects model will be conducted that includes the surgeon as a random effect in the main 
primary models. If there are enough surgeons per centre, we will include centre as a fixed effect and 
surgeon as a random effect. If there are too few then we will simply replace centre with surgeon in 
the model.  
 
3.6.6 Exploratory Analyses 
Bladder diaries will be collected and analysed. Although not part of this analysis plan, these will be 
explored in future analyses. 
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4. Final report tables and figures (subject to change) 
Figure 1. CONSORT diagram  
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Table 1. Baseline Characteristics between each treatment arm 
  ThuVARP  TURP 
 n* Mean (SD) or n (%) n* Mean (SD) or n (%) 
Total number of participants     
Age(years)     
Bothersome LUTS     
Urinary retention     
BMI (on day of surgery)     
Centre 
Bristol     
Aberdeen     
Newcastle     
Leeds     
Swindon     
Cheltenham     
Truro     
Ethnicity 
White     
Black/African/Caribbean/Black British     
Mixed/Multiple ethnic groups     
Asian/Asian British     
Other ethnic group     
Disclosure declined     
Comorbidities at baseline (from the Charlson Comorbidity Index) 
None     
One     
More than one     
Urinary measures 
Maximum flow rate (Qmax)     
Post-void residual (PVR)     
Voided volume (VV)     
Has the patient had Urodynamics?     
Catheterisation  
In use     
      Intermittent     
      Indwelling     
Prostate tests 
PSA test     
TRUS     
DRE     
Prostate size: Normal     
Prostate size: Suspicious     
Blood tests 
Is the patient on anticoagulants?     
Sodium (total)     
Creatinine     
Haemoglobin     
Platelets     
White cell count     
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Haematocrit     
IPSS: Symptom severity at baseline 
Incomplete Emptying     
Frequency     
Intermittency     
Urgency     
Weak Stream     
Straining     
Nocturia     
Total IPSS score     
IPSS QoL     
ICIQ MLUTS 
Voiding score~     
Incontinence score#     
Daytime frequency (>8 times)     
Nocturia (>1 times per night)     
ICIQ MLUTS – sexual matters 
Erections (reduced or none)     
Ejaculation (reduced or none)     
Painful ejaculation (Yes)     
Urinary symptoms affected sex life?     
IIEF - 5 
Erectile dysfunction score+     
*n analysable, ~On a scale of 0-20 with larger scores indicating more severe symptoms, #On a scale of 0-24 with larger scores indicating 
more severe symptoms, +Lower scores indicate more severe erectile dysfunction (5-7=severe, 8-11=moderate, 12-16=mild to moderate, 
17-21=mild, 22-25=none) 
 
 
Table 2. Primary and secondary outcomes for PROMS and Qmax, difference between arms 
Variable 
ThuVARP 
Mean (SD) 
TURP 
Mean (SD) 
Difference in means* 
(95% C.I.) 
P value* 
Primary analysis 
TOTAL IPSS Score     
Qmax score     
Secondary analysis (ICIQ-MLUTS) 
ICSmaleVS (voiding scale)~     
ICSmaleIS (incontinence scale)#     
Daytime frequency (>8 times)     
Nocturia (>1 times per night)     
Secondary analysis (ICIQ-MLUTSsex) 
Erections (reduced or none)     
Ejaculation (reduced or none)     
Painful ejaculation (Yes)     
Urinary symptoms affected sex life?     
Secondary analysis (IIEF) 
Erectile dysfunction score+     
*Adjusted for centre and whether the patient had retention or LUTS at baseline 
~Voiding scale, on a scale of 0-20 with larger scores indicating more severe symptoms  
#Incontinence scale, on a scale of 0-24 with larger scores indicating more severe symptoms 
+Lower scores indicate more severe erectile dysfunction (5-7=severe, 8-11=moderate, 12-16=mild to moderate, 17-21=mild, 22-25=none) 
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Table 3a. Surgical complications and Clavien Dindo scores per patient~ 
*Ordinal logistic regression adjusted for centre and whether the patient had retention or LUTS at baseline, ~Where patients experienced 
multiple grading within one complication type, the highest was taken 
 
Table 3b. Additional surgical outcomes 
 
 
 
Variable ThuVARP TURP Difference* P value 
 n (%) n (%)   
Bleeding 
Not experienced   
  
CD grade I   
CD grade II   
CD grade III   
CD grade IV   
CD grade V   
Infection (sepsis, UTI, abscess) 
Not experienced   
  
CD grade I   
CD grade II   
CD grade III   
CD grade IV   
CD grade V   
Retrograde ejaculation 
Not experienced   
  
CD grade I   
CD grade II   
CD grade III   
CD grade IV   
CD grade V   
....... 
Not experienced   
  
CD grade I   
CD grade II   
CD grade III   
CD grade IV   
CD grade V   
Variable 
ThuVARP 
n (%)/Mean(SD) 
TURP 
n (%)/Mean(SD) 
Difference* 
(95% C.I.) 
P value* 
Surgery outcomes 
Length of hospital stay (hours)     
Transfusion required (Y/N)     
Post-operative catheterisation time     
Catheter required at 3m?     
Catheter required at 12m?     
Haemoglobin – blood loss     
Serum sodium     
Post-void residual volume     
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Table 4. Secondary Outcome. Satisfaction with treatment 
Variable 
ThuVARP 
n(%) 
TURP 
n(%) 
Difference* (95% C.I.) P value* 
Overall scores 
Overall how satisfied were you1 (0-10)?     
Median total questionnaire score2 (iqr)     
*Adjusted for centre and whether the patient had retention or LUTS at baseline 
1Higher scores indicate better satisfaction 
2Lower scores indicate better satisfaction 
 
 
Table 5. Secondary Outcome. Quality of life 
Variable 
ThuVARP 
n(%)/Mean(SD) 
TURP 
n(%)/Mean(SD) 
Difference* (95% C.I.) P value* 
IPSS QoL 
Quality of life (0-7)     
ICIQ QoL subscores~ 
Role limitations     
Physical limitations   
 
 
Social limitations    
Personal relationships     
Emotions     
Sleep/energy     
Severity measures     
ICIQ Urinary symptoms effect on... 
Getting embarrassed     
Overall interference with everyday life     
* Adjusted for centre and whether the patient had retention or LUTS at baseline, ~Based on the Kings Health Questionnaire 
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Table 6. Sensitivity Analyses: IPSS and Qmax Scores, difference between arms 
*Adjusted for centre & whether the patient had retention or LUTS at baseline, 1Removing those who did not comply with their randomised 
treatment, 2Unbiased estimates to account for patient crossover, 3Patients who found out their allocation prior to completing the 12 
months questionnaire, 4Respective baseline measures for the IPSS and Qmax, 5Imbalances at baseline by more than 10%/0.5 SDs, 
6Comparison of 3 groups: ThuVARP, monopolar TURP and bipolar TURP, 7A mixed effects model will be conducted that includes the 
surgeon as a random effect 
 
 
 
Table 7. Subgroup Analyses: Primary outcomes  
 IPSS score at 12 months£ Qmax at 12 months£ 
Variable 
Subgroup specific 
MD (95% C.I) 
Interaction effect 
MD (95% C.I); p 
Subgroup specific 
MD (95% C.I) 
Interaction effect 
MD (95% C.I); p  
Subgroup analyses 
Baseline diagnosis     
     LUTS  
 
 
 
     Urinary retention   
Age     
     <Median  
 
 
 
     ≥Median   
Peri-operative prostate size (DRE)     
     Small (<40g)  
 
 
 
     Medium (40-60g)   
     Large (60-80g)   
     Very large (>80g)   
Comorbidities at baseline     
     With  
 
 
 
     Without   
MD refers to difference in means, £Linear regression model adjusting for centre and baseline diagnosis where appropriate 
 
 
 
Variable 
ThuVARP 
Mean (SD) 
TURP 
Mean (SD) 
Difference in means* 
(95% C.I.) 
P value* 
Sensitivity: IPSS Symptom Score 
Complete case analysis     
Per protocol1     
CACE analysis2     
Removal of patients3     
Adj. for baseline4     
Adj. for imbalance5     
Type of TURP/surgery6     
Surgeon effects7     
Sensitivity: Qmax Score 
Complete case analysis     
Per protocol1     
CACE analysis2     
Removal of patients3     
Adj. for baseline4     
Adj. for imbalance5     
Type of TURP/surgery6     
Surgeon effects7     
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